Entera Bio

Q2 FY2026 EarningsQ2 FY26 results missed consensus estimates on profitability due to increased R&D and significant non-cash financial expenses. Revenue was in-line at $0.0M, consistent with a clinical-stage biotech. Operating loss of $4.6M and EPS GAAP of -$0.14 missed the mean expectations of -$4.4M and -$0.08, respectively. The variance was primarily driven by a $2.7M non-cash charge from the fair value remeasurement of April 2026 pre-funded warrants. A transformative $275M private placement in July 2026 significantly de-risks the balance sheet, extending the cash runway into 2030.